[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201600979SA - Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor - Google Patents

Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor

Info

Publication number
SG11201600979SA
SG11201600979SA SG11201600979SA SG11201600979SA SG11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA SG 11201600979S A SG11201600979S A SG 11201600979SA
Authority
SG
Singapore
Prior art keywords
methyl
furo
thiazol
hexahydro
ethynyl
Prior art date
Application number
SG11201600979SA
Inventor
Urszula Grabowska
Lourdes Salvadore-Oden
Perez Victor M Diaz
Andrew Carr
Original Assignee
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivir Ab filed Critical Medivir Ab
Publication of SG11201600979SA publication Critical patent/SG11201600979SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11201600979SA 2013-08-13 2014-08-13 Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor SG11201600979SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1314503.2A GB201314503D0 (en) 2013-08-13 2013-08-13 Cysteine protease inhibitor salt
PCT/EP2014/067374 WO2015022385A1 (en) 2013-08-13 2014-08-13 Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor

Publications (1)

Publication Number Publication Date
SG11201600979SA true SG11201600979SA (en) 2016-03-30

Family

ID=49262126

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201600979SA SG11201600979SA (en) 2013-08-13 2014-08-13 Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor

Country Status (17)

Country Link
US (1) US9650388B2 (en)
EP (1) EP3033345B1 (en)
JP (1) JP6530752B2 (en)
KR (1) KR102271944B1 (en)
CN (1) CN105612160B (en)
AU (1) AU2014307850B8 (en)
BR (1) BR112016003169B1 (en)
CA (1) CA2920797C (en)
EA (1) EA032409B1 (en)
GB (1) GB201314503D0 (en)
HK (1) HK1218915A1 (en)
MX (1) MX369144B (en)
MY (1) MY180170A (en)
SG (1) SG11201600979SA (en)
TW (1) TWI648278B (en)
WO (1) WO2015022385A1 (en)
ZA (1) ZA201600952B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024162890A1 (en) * 2023-02-03 2024-08-08 Medivir Ab Treatment of lcpd with a cathepsin k inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0817425D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
GB0817424D0 (en) * 2008-09-24 2008-10-29 Medivir Ab Protease inhibitors
BR112012013861A2 (en) * 2009-12-10 2017-09-26 Medivir Uk Ltd cysteine protease inhibitors

Also Published As

Publication number Publication date
CN105612160A (en) 2016-05-25
KR102271944B1 (en) 2021-07-02
MX369144B (en) 2019-10-30
KR20160042107A (en) 2016-04-18
AU2014307850A1 (en) 2016-03-03
JP2016530260A (en) 2016-09-29
ZA201600952B (en) 2017-07-26
US20160194334A1 (en) 2016-07-07
JP6530752B2 (en) 2019-06-12
TWI648278B (en) 2019-01-21
HK1218915A1 (en) 2017-03-17
EA201690373A1 (en) 2016-07-29
BR112016003169B1 (en) 2023-02-23
AU2014307850B8 (en) 2017-03-02
TW201536788A (en) 2015-10-01
MX2016001978A (en) 2017-01-26
EP3033345A1 (en) 2016-06-22
US9650388B2 (en) 2017-05-16
CA2920797C (en) 2021-06-15
GB201314503D0 (en) 2013-09-25
CA2920797A1 (en) 2015-02-19
AU2014307850A8 (en) 2017-03-02
WO2015022385A1 (en) 2015-02-19
BR112016003169A2 (en) 2017-08-01
MY180170A (en) 2020-11-24
CN105612160B (en) 2017-11-24
EA032409B1 (en) 2019-05-31
EP3033345B1 (en) 2017-07-26
AU2014307850B2 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
MY180083A (en) Tetrahydropyrrolothiazine compounds
NZ727601A (en) Dihydropyrimido fused ring derivative as hbv inhibitor
ZA201903093B (en) Crystalline forms of a magl inhibitor
WO2014132270A3 (en) Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
EP3619208C0 (en) Crystalline forms of a jak inhibitor compound
JO3318B1 (en) Bace inhibitors
MA39866A (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MX2015015841A (en) Phenoxyethyl dihydro-1h-isoquinoline compounds.
MX2020003020A (en) Aminocarbonylcarbamate compounds.
MX2019007629A (en) Process for the preparation of a 2-pyridylethylcarboxamide derivative.
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
MX2022009281A (en) Inhibitors of rorï’.
EP3371196A4 (en) Heterocyclic compounds as inhibitors of platelet aggregation
ZA201600952B (en) Form 2 crystalline polymorph of a salt of n-[1-6-(ethynyl-3-oxo-hexahydro-furo[3,2-b]pyrrole-4-carbonyl)-3-methyl-butyl]-4-[5-fluoro-2-(4-methyl-piperazinyl)thiazol-4-yl]-benzamide useful as cysteine protease inhibitor
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
EA201690593A1 (en) NEW UREA COMPOUNDS
HK1252841A1 (en) Crystalline forms of hydrochloride salts of thienopyrimidine compound
IN2013MU00777A (en)
EP3708165A4 (en) Crystal form i of a 5-aminopyrazole carboxamide compound as btk inhibitor